Subscribe to newsletter Subscribe to newsletter Subscribe to newsletter Subscribe to newsletter Subscribe to newsletter Subscribe to newsletter

Cost-effective reimbursement analysis for medical technologies in Europe

Procedure coding, payment mechanism, reimbursement tariffs, policy, and HTA considerations in 15 EU countries

Learn more

White Paper: Evidence Requirements for the Creation of IVD Reimbursement (NABM) Codes in France

Get insights from MTRC White Papers to advance your understanding on HAS assessments and evidence generation strategy for IVD tests in France

Request free of charge
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

Recent news and posts

Tags

Use tags to find relevant records
3D printed implants
Ablation methods
Allogeneic mesenchymal stem cells
Ambulatory ECG monitoring
Aortic abdominal aneurysm
Aortic root replacement
Arthroplasty
Arthroscopy
Assisted ventilation
Atherectomy
Austria
Autologous chondrocyte implantation
Automated external defibrillator
AV fistula
AV graft
Balloon kyphoplasty
Bariatric surgery
Baroreflex activation therapy
Barrett’s oesophagus
Belgium
Benign prostatic hyperplasia
Biopsy
Bone Conductive Hearing Device
Breast reconstruction
Bronchial thermoplasty
Burns
Caesarean section
Cancer
Capsule endoscopy
Carbon ion therapy
Cardiac ablation
Cardiac computer tomography
Cardiac pacemaker
Cardiac resynchronization therapy
Cardiac Resynchronization Therapy Defibrillator (CRT-D)
Cardiovascular devices
Cardiovascular procedures
Carotid endarterectomy
Cataract
Cell therapy
Cesarean section
Cholecystectomy
Chronic obstructive pulmonary disease
Chronic wounds
Clinical guidelines
Cochlear implants
Commissioning
Companion diagnostic tests
Computed tomography
Conditional reimbursement
Connected medical devices
Continuous glucose monitoring (CGM)
Coronary interventions
Coronary percutaneous revascularization procedures
Coronary procedures
Coronavirus
See all tags

New version of the NABM nomenclature released in France

The Nomenclature of Medical Biology Procedures (NABM) serves as the primary and permanent reimbursement catalog for in-vitro diagnostic tests covered under statutory health insurance in France.

On February 23, 2026, a new version of the Nomenclature (NABM 102), effective from March 3, 2026, was released. 

One new code, 4364 "Detection of plasmodial proteins in blood by ICG" (coefficient B-42) was introduced. To obtain the tariff, the coefficient (i.e.,42) should be multiplied by the B value, which is €0.25 for metropolitan France.

The other updates concern the deletion and modification of several codes in the toxicology, parasitology, and serology sections.

See the details in French here (NABM) and here (Order on NABM v.102 changes) 

This news is just one of about 300 market access news collected by our team in the premium subscription service Market Access Monitor every week from more than 80 organizations. Access our paid service to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Access is organized as an online Database and email alert formats. Contact us to get a free, three-month, no-obligation trial.

Tags
France
Reimbursement
In-vitro diagnostic tests

The latest related news

25
Feb 2026

Five more health apps have obtained reimbursement in Germany since August 2025

In Germany, digital health applications (DiGAs) that can be prescribed by physicians and psychotherapists and reimbursed by statutory health insurers are listed in the Directory of Digital Health Applications maintained by the Federal Institute for Drugs and Medical Devices (BfArM). As of February 23, 2026, a total of 61 apps are available in the Directory and thus eligible for reimbursement.
Read more
19
Feb 2026

Order updating the regulation of point-of-care tests released in France

On February 7, 2026, the Ministry of Health, Family, Autonomy and People with Disability released an update of the 2014 regulations on conditions of performing IVD tests outside the medical biology laboratory. The new regulation expands the list of locations eligible for point-of-care testing (POCT) and provides an explicit list of tests that can be performed as POCT, and links them to eligible locations. It also introduces a quality assurance framework, accreditation requirements, and mandates that comprehensive conventions be concluded between the remote sites providing POCT and the responsible laboratories.
Read more
17
Feb 2026

National Cancer Plan for the Next Decade Released in England

On February 4, 2026, the Department of Health and Social Care and NHS England published the National Cancer Plan for England, setting out a decade-long, technology-enabled transformation of cancer services, with substantial commitments to diagnostics, AI, genomics, robotic surgery, digital tools, and innovation-driven care pathways. The key ambition is that, by 2035, three out of four people diagnosed with cancer will be cancer-free, or living well with cancer after five years.
Read more
16
Feb 2026

New topics for implementation within the Dutch “Care Evaluation and Appropriate Use” program

In January 2026, nine new topics were added to the Implementation Agenda of the Care Evaluation and Appropriate Use (ZE&GG) program, requiring healthcare providers to implement these evidence-based practices in daily care and to demonstrate results within two years. The topics concerned the in-vitro diagnostic, gastrointestinal, and ENT fields. Additionally, 16 topics were removed from the agenda, as most had been sufficiently implemented and others were no longer relevant.
Read more